230 related articles for article (PubMed ID: 29966760)
21. Busulfan dose intensity and outcomes in reduced-intensity allogeneic peripheral blood stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia.
Chen YB; Coughlin E; Kennedy KF; Alyea EP; Armand P; Attar EC; Ballen KK; Cutler C; Dey BR; Koreth J; McAfee SL; Spitzer TR; Antin JH; Soiffer RJ; Ho VT
Biol Blood Marrow Transplant; 2013 Jun; 19(6):981-7. PubMed ID: 23562738
[TBL] [Abstract][Full Text] [Related]
22. Allogeneic Stem Cell Transplantation from HLA-Mismatched Donors for Pediatric Patients with Acute Lymphoblastic Leukemia Treated According to the 2003 BFM and 2007 International BFM Studies: Impact of Disease Risk on Outcomes.
Dalle JH; Balduzzi A; Bader P; Lankester A; Yaniv I; Wachowiak J; Pieczonka A; Bierings M; Yesilipek A; Sedlaçek P; Ifversen M; Sufliarska S; Toporski J; Glogova E; Poetschger U; Peters C
Biol Blood Marrow Transplant; 2018 Sep; 24(9):1848-1855. PubMed ID: 29772352
[TBL] [Abstract][Full Text] [Related]
23. Missing HLA C group 1 ligand in patients with AML and MDS is associated with reduced risk of relapse and better survival after allogeneic stem cell transplantation with fludarabine and treosulfan reduced toxicity conditioning.
Shimoni A; Vago L; Bernardi M; Yerushalmi R; Peccatori J; Greco R; Shem-Tov N; Lo Russo A; Danylesko I; Apel A; Bonini C; Lupo Stanghellini MT; Nagler A; Ciceri F
Am J Hematol; 2017 Oct; 92(10):1011-1019. PubMed ID: 28631269
[TBL] [Abstract][Full Text] [Related]
24. Who is the best hematopoietic stem-cell donor for a male patient with acute leukemia?
Ringdén O; Labopin M; Solders M; Beelen D; Arnold R; Ehninger G; Milpied N; Niederwieser D; Hamladji RM; Kyrcz-Krzemien S; Ganser A; Socié G; Stelljes M; Volin L; Craddock C; Mohty M;
Transplantation; 2014 Sep; 98(5):569-77. PubMed ID: 24798307
[TBL] [Abstract][Full Text] [Related]
25. The impact of HLA-matching on reduced intensity conditioning regimen unrelated donor allogeneic stem cell transplantation for acute myeloid leukemia in patients above 50 years-a report from the EBMT acute leukemia working party.
Rubio MT; Savani BN; Labopin M; Polge E; Niederwieser D; Ganser A; Schwerdtfeger R; Ehninger G; Finke J; Renate A; Craddock C; Kröger N; Hallek M; Jindra P; Mohty M; Nagler A
J Hematol Oncol; 2016 Aug; 9(1):65. PubMed ID: 27488518
[TBL] [Abstract][Full Text] [Related]
26. Matched unrelated or matched sibling donors result in comparable outcomes after non-myeloablative HSCT in patients with AML or MDS.
Robin M; Porcher R; Adès L; Boissel N; Raffoux E; Xhaard A; Larghero J; Gardin C; Himberlin C; Delmer A; Fenaux P; Dombret H; Socié G; Peffault de Latour R
Bone Marrow Transplant; 2013 Oct; 48(10):1296-301. PubMed ID: 23584440
[TBL] [Abstract][Full Text] [Related]
27. Outcome after allogeneic stem cell transplantation with haploidentical versus HLA-matched donors in patients with higher-risk MDS.
Michel C; Robin M; Morisset S; Blaise D; Maertens J; Chevalier P; Castilla-Llorente C; Forcade E; Ceballos P; Yakoug-Agha I; Poire X; Carre M; Bay JO; Beguin Y; Loschi M; Huynh A; Guillerm G; François S; Mear JB; Duléry R; Suarez F; Bilger K; Cornillon J; Chalandon Y; Maillard N; Labussière-Wallet H; Charbonnier A; Turlure P; Berceanu A; Chantepie S; Maury S; Bazarbachi A; Menard AL; Nguyen-Quoc S; Rubio MT; D'Aveni M
Bone Marrow Transplant; 2023 May; 58(5):534-543. PubMed ID: 36774430
[TBL] [Abstract][Full Text] [Related]
28. Alternative Donor Graft Sources for Adults with Hematologic Malignancies: A Donor for All Patients in 2017!
Kindwall-Keller TL; Ballen KK
Oncologist; 2017 Sep; 22(9):1125-1134. PubMed ID: 28546462
[TBL] [Abstract][Full Text] [Related]
29. Donor-recipient killer immunoglobulin like receptor (KIR) genotype matching has a protective effect on chronic graft versus host disease and relapse incidence following HLA-identical sibling hematopoietic stem cell transplantation.
Sahin U; Dalva K; Gungor F; Ustun C; Beksac M
Ann Hematol; 2018 Jun; 97(6):1027-1039. PubMed ID: 29549412
[TBL] [Abstract][Full Text] [Related]
30. Impact of the source of hematopoietic stem cell in unrelated transplants: comparison between 10/10, 9/10-HLA matched donors and cord blood.
Granier C; Biard L; Masson E; Porcher R; Peffault de Latour R; Robin M; Boissel N; Xhaard A; Ribaud P; Lengline E; Larghero J; Charron D; Loiseau P; Socié G; Dhédin N
Am J Hematol; 2015 Oct; 90(10):897-903. PubMed ID: 26149659
[TBL] [Abstract][Full Text] [Related]
31. Unrelated donor versus matched sibling donor in adults with acute myeloid leukemia in first relapse: an ALWP-EBMT study.
Ruggeri A; Battipaglia G; Labopin M; Ehninger G; Beelen D; Tischer J; Ganser A; Schwerdtfeger R; Glass B; Finke J; Michallet M; Stelljes M; Jindra P; Arnold R; Kröger N; Mohty M; Nagler A
J Hematol Oncol; 2016 Sep; 9(1):89. PubMed ID: 27639553
[TBL] [Abstract][Full Text] [Related]
32. Effect of graft source on unrelated donor hemopoietic stem cell transplantation in adults with acute myeloid leukemia after reduced-intensity or nonmyeloablative conditioning: a study from the Société Francaise de Greffe de Moelle et de Thérapie Cellulaire.
Malard F; Milpied N; Blaise D; Chevallier P; Michallet M; Lioure B; Clément L; Hicheri Y; Cordonnier C; Huynh A; Yakoub-Agha I; Peffault de Latour R; Mohty M
Biol Blood Marrow Transplant; 2015 Jun; 21(6):1059-67. PubMed ID: 25708220
[TBL] [Abstract][Full Text] [Related]
33. MHC Class I Chain-Related Gene A (MICA) Donor-Recipient Mismatches and MICA-129 Polymorphism in Unrelated Donor Hematopoietic Cell Transplantations Has No Impact on Outcomes in Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, or Myelodysplastic Syndrome: A Center for International Blood and Marrow Transplant Research Study.
Askar M; Sobecks R; Wang T; Haagenson M; Majhail N; Madbouly A; Thomas D; Zhang A; Fleischhauer K; Hsu K; Verneris M; Lee SJ; Spellman SR; Fernández-Viña M
Biol Blood Marrow Transplant; 2017 Mar; 23(3):436-444. PubMed ID: 27987385
[TBL] [Abstract][Full Text] [Related]
34. Younger unrelated donors may be preferable over HLA match in the PTCy era: a study from the ALWP of the EBMT.
Sanz J; Labopin M; Choi G; Kulagin A; Peccatori J; Vydra J; Reményi P; Versluis J; Rovira M; Blaise D; Labussière-Wallet H; Montoro J; Sica S; Meijer E; Itälä-Remes M; Schaap N; Bulabois CE; Piemontese S; Mohty M; Ciceri F
Blood; 2024 Jun; 143(24):2534-2543. PubMed ID: 38657278
[TBL] [Abstract][Full Text] [Related]
35. Interferon-α: A Potentially Effective Treatment for Minimal Residual Disease in Acute Leukemia/Myelodysplastic Syndrome after Allogeneic Hematopoietic Stem Cell Transplantation.
Mo XD; Zhang XH; Xu LP; Wang Y; Yan CH; Chen H; Chen YH; Han W; Wang FR; Wang JZ; Liu KY; Huang XJ
Biol Blood Marrow Transplant; 2015 Nov; 21(11):1939-47. PubMed ID: 26116088
[TBL] [Abstract][Full Text] [Related]
36. Donor Killer Immunoglobulin-Like Receptor Profile Bx1 Imparts a Negative Effect and Centromeric B-Specific Gene Motifs Render a Positive Effect on Standard-Risk Acute Myeloid Leukemia/Myelodysplastic Syndrome Patient Survival after Unrelated Donor Hematopoietic Stem Cell Transplantation.
Bao X; Wang M; Zhou H; Zhang H; Wu X; Yuan X; Li Y; Wu D; He J
Biol Blood Marrow Transplant; 2016 Feb; 22(2):232-239. PubMed ID: 26371372
[TBL] [Abstract][Full Text] [Related]
37. A comparison between allogeneic stem cell transplantation from unmanipulated haploidentical and unrelated donors in acute leukemia.
Piemontese S; Ciceri F; Labopin M; Arcese W; Kyrcz-Krzemien S; Santarone S; Huang H; Beelen D; Gorin NC; Craddock C; Gulbas Z; Bacigalupo A; Mohty M; Nagler A;
J Hematol Oncol; 2017 Jan; 10(1):24. PubMed ID: 28103944
[TBL] [Abstract][Full Text] [Related]
38. Improving Revised International Prognostic Scoring System Pre-Allogeneic Stem Cell Transplantation Does Not Translate Into Better Post-Transplantation Outcomes for Patients with Myelodysplastic Syndromes: A Single-Center Experience.
Alzahrani M; Power M; Abou Mourad Y; Barnett M; Broady R; Forrest D; Gerrie A; Hogge D; Nantel S; Sanford D; Song K; Sutherland H; Toze C; Nevill T; Narayanan S
Biol Blood Marrow Transplant; 2018 Jun; 24(6):1209-1215. PubMed ID: 29474870
[TBL] [Abstract][Full Text] [Related]
39. A conditioning platform based on fludarabine, busulfan, and 2 days of rabbit antithymocyte globulin results in promising results in patients undergoing allogeneic transplantation from both matched and mismatched unrelated donor.
Devillier R; Fürst S; Crocchiolo R; El-Cheikh J; Castagna L; Harbi S; Granata A; D'Incan E; Coso D; Chabannon C; Picard C; Etienne A; Calmels B; Schiano JM; Lemarie C; Stoppa AM; Bouabdallah R; Vey N; Blaise D
Am J Hematol; 2014 Jan; 89(1):83-7. PubMed ID: 24108528
[TBL] [Abstract][Full Text] [Related]
40. Human leukocyte antigen-E mismatch is associated with better hematopoietic stem cell transplantation outcome in acute leukemia patients.
Tsamadou C; Fürst D; Vucinic V; Bunjes D; Neuchel C; Mytilineos D; Gramatzki M; Arnold R; Wagner EM; Einsele H; Müller C; Schrezenmeier H; Mytilineos J
Haematologica; 2017 Nov; 102(11):1947-1955. PubMed ID: 28883078
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
